Clinical trials: Placebo Control Design
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated
The main objectives of this trial are to investigate (1) safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising doses of BI 1569912; (2) tolerability of BI 1569912 in an up-titrating dosing scheme.
- Trial name
- NCT04978506
- Testing
- BI 1569912
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ageing
Study to Assess the Effect of Leucine Along With Resistance Exercise on Muscle Strength and Quality of Life in Elders
The purpose of this study is to determine whether a nutritional supplement with an amino acid called leucine along with resistance exercise are effective in the improvement of muscle strength and quality of life in elderly people.
- Trial name
- NCT00929929
- Testing
- L-leucine., Maltodextrin., Exercise program.
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Healthy
Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers
Determination of the ability to drive and operate machines after single and multiple oral dose of Neramexane as compared to placebo
- Trial name
- NCT00712283
- Testing
- Neramexane mesylate
- Where
- Germany
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Healthy
A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 764122 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03794323
- Testing
- BI 764122
- Where
- Belgium
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood
Effects of multiple rising doses of BI 1839100 on safety, tolerability, pharmacokinetics and the effect of high-fat meal on pharmacokinetics of BI 1839100 will be assessed as well as assessing potential drug-drug interactions.
- Trial name
- NCT05738291
- Testing
- BI 1839100, midazolam, digoxin
- Where
- Netherlands
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Person
ZL-82 Double-blind Clinical Trial
ZL-82 tablets are highly selective covalent irreversible inhibitors of non-receptor tyrosine protein kinase 3 (Janus kinase 3, JAK3) developed by Chengdu Zenitar Biomedical Technology Co., Ltd. According to Document No.
- Trial name
- NCT06432738
- Testing
- ZL-82
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Healthy, Obesity
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
This study is open to adults between 18 and 55 years of age who are living with overweight or obesity. People with a body mass index (BMI) from 27 to 40 kg/m2 can join the study.
- Trial name
- NCT05751226
- Testing
- BI 1820237, semaglutide, BI 456906
- Where
- Germany
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated
This first-in man trial is designed to investigate the safety and tolerability of BI 894416 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03315936
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321
The main objectives are: Part I: To investigate safety, tolerability, and pharmacokinetics (PK) of BI 706321 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03971695
- Testing
- BI 706321
- Where
- Germany
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3810477 in healthy male subjects.
- Trial name
- NCT06631430
- Testing
- BI 3810477
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 765423 in healthy male subjects following intravenous administration of single rising doses.
- Trial name
- NCT05658107
- Testing
- BI 765423
- Where
- Belgium
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Dyspareunia
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.
- Trial name
- NCT05617820
- Testing
- Estradiol, Imvexxy
- Where
- 48 sites in United States, El Salvador and 1 more
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food
Safety, pharmacodynamics and pharmacokinetics of 0.25, 0.75, 2.0, 6.0, and 10 mg BIBB 1464 p.o once daily in a rising dose group-comparison (placebo controlled, double blind, randomized per dose level).
- Trial name
- NCT02229838
- Testing
- BIBB 1464 MS tablet, BIBB 1464 MS solution, Standard dinner
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics and pharmacodynamics of BI 3731579 in healthy volunteers following administration of multiple rising doses per day over 15 days.
- Trial name
- NCT06716190
- Testing
- Mid-dose bid BI 3731579, Midazolam, Low-dose bid BI 3731579
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How BI 474121 is Tolerated
Safety, tolerability, and pharmacokinetics of BI 474121 will be assessed in healthy Japanese male using single rising oral doses in order to provide the basis for an ongoing clinical development of BI 474121 for the treatment of…
- Trial name
- NCT04964453
- Testing
- BI 474121
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hunger
Study of Psyllium 6.8 g Versus Placebo on Satiety in Healthy Volunteers
This is a randomized, double-blind, placebo-controlled, 2-treatment, 3-period crossover design study to evaluate the effects of psyllium 6.8 g provided as sugarfree Metamucil fiber supplement powder dissolved in water versus…
- Trial name
- NCT01809925
- Testing
- psyllium fiber 6.8g
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Healthy
A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men
This trial aims to investigate safety, tolerability, and pharmacokinetics following multiple rising doses of BI 1815368 in healthy male subjects.
- Trial name
- NCT05857878
- Testing
- BI 1815368
- Where
- Belgium
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Elevated Low-Density Lipoprotein Cholesterol
Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single and multiple dose escalation study with SC doses of SNK-396 in participants with elevated LDL-C.
- Trial name
- NCT05896969
- Testing
- SNK-396 - SAD cohort, SNK-396 - MAD Cohort
- Where
- 3 sites in Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Healthy
Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects
Investigation of safety, tolerability, pharmacokinetics and pharmacodynamics of single rising doses of BI 705564 and of the food effect on BI 705564 in healthy male subjects
- Trial name
- NCT03123185
- Testing
- BI 705564 (Test), BI 705564 (Reference)
- Where
- Germany
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)
This is phase 1 investigator-and-subject blind, sponsor open, randomized, placebo controlled, parallel study in healthy subjects to evaluate the pharmacodynamics effect of single oral doses of PF-06648671 on CSF Aβ concentrations…
- Trial name
- NCT02407353
- Testing
- PF-06648671
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer